{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:05:34Z","timestamp":1790949934758,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.aohep.2023.101280","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T21:07:58Z","timestamp":1705612078000},"page":"101280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-3403","authenticated-orcid":false,"given":"Jeremy","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8368-1478","authenticated-orcid":false,"given":"Paul N.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"MacPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.aohep.2023.101280_bib0001","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9958","key":"10.1016\/j.aohep.2023.101280_bib0002","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(14)61838-9","article-title":"Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis","volume":"384","author":"Williams","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.aohep.2023.101280_bib0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0004","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"10290","key":"10.1016\/j.aohep.2023.101280_bib0005","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.aohep.2023.101280_bib0006","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41575-023-00796-x","article-title":"Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach","volume":"20","author":"Brennan","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2023.101280_bib0007","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.dsx.2019.03.009","article-title":"Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: a cross-sectional study in north of Iran","volume":"13","author":"Mansour-Ghanaei","year":"2019","journal-title":"Diabetes Metabolic Syndrome: Clin Res Rev"},{"issue":"25","key":"10.1016\/j.aohep.2023.101280_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13250","article-title":"Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE)","volume":"13","author":"Donnan","year":"2009","journal-title":"Health Technol Assess"},{"issue":"Supplement_1","key":"10.1016\/j.aohep.2023.101280_bib0009","doi-asserted-by":"crossref","first-page":"s49","DOI":"10.2337\/dc23-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes 2023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0010","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/jalm\/jfaa109","article-title":"Intelligent liver function testing: working smarter to improve patient outcomes in liver disease","volume":"5","author":"Macpherson","year":"2020","journal-title":"J Appl Lab Med"},{"issue":"6","key":"10.1016\/j.aohep.2023.101280_bib0011","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archinternmed.2007.131","article-title":"Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels","volume":"168","author":"Neuschwander-Tetri","year":"2008","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.aohep.2023.101280_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.aohep.2023.101280_bib0013","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0014","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4103\/2230-8210.163172","article-title":"Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes","volume":"19","author":"Sanyal","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.aohep.2023.101280_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2023.101280_bib0016","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0017","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jhep.2004.07.010","article-title":"Silent non-alcoholic fatty liver disease a clinical histological study","volume":"41","author":"Sorrentino","year":"2004","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2023.101280_bib0018","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0019","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.23505","article-title":"Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology","volume":"51","author":"Lee","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.aohep.2023.101280_bib0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1440-1746.2010.06481.x","article-title":"Healthy range for serum ALT and the clinical significance of \"unhealthy\" normal ALT levels in the Korean population","volume":"26","author":"Kang","year":"2011","journal-title":"J. Gastroenterol Hepatol."},{"issue":"2","key":"10.1016\/j.aohep.2023.101280_bib0021","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.24725","article-title":"Upper limits of normal for alanine aminotransferase activity in the United States population","volume":"55","author":"Ruhl","year":"2012","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.aohep.2023.101280_bib0022","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep4.1794","article-title":"Definition of healthy ranges for alanine aminotransferase levels: a 2021 update","volume":"5","author":"Valenti","year":"2021","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.aohep.2023.101280_bib0023","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2019.05.033","article-title":"Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care","volume":"71","author":"Dillon","year":"2019","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.aohep.2023.101280_bib0024","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/flgastro-2017-100909","article-title":"Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the 'intelligent LFT' pathway for the automated assessment of deranged liver enzymes","volume":"9","author":"Miller","year":"2018","journal-title":"Frontline Gastroenterol"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0025","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0026","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrgastro.2018.10","article-title":"Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD","volume":"15","author":"Tapper","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.aohep.2023.101280_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0028","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.aohep.2023.101280_bib0029","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/2050640619865133","article-title":"Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease","volume":"7","author":"Staufer","year":"2019","journal-title":"United Eur Gastroenterol J"},{"issue":"4","key":"10.1016\/j.aohep.2023.101280_bib0030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.15403\/jgld-293","article-title":"Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels","volume":"28","author":"Ulasoglu","year":"2019","journal-title":"J Gastrointestin Liver Dis"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0031","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101280_bib0032","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cca.2013.03.030","article-title":"Upper limit of normal for alanine aminotransferase: quo vadis?","volume":"422","author":"Pacifico","year":"2013","journal-title":"Clinica Chimica Acta"},{"issue":"5","key":"10.1016\/j.aohep.2023.101280_bib0033","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/flgastro-2021-101833","article-title":"Identification of liver disease: why and how","volume":"13","author":"Macpherson","year":"2022","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2023.101280_bib0034","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/hep.22109","article-title":"Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease","volume":"47","author":"Kim","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2023.101280_bib0035","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101280_bib0036","article-title":"Can we use old NAFLD data under the new MASLD definition?","author":"Song","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2023.101280_bib0037","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","author":"Hagstr\u00f6m","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.aohep.2023.101280_bib0038","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/flgastro-2019-101177","article-title":"The development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community","volume":"11","author":"Chalmers","year":"2020","journal-title":"Frontline Gastroenterol"},{"issue":"7","key":"10.1016\/j.aohep.2023.101280_bib0039","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.cgh.2017.12.048","article-title":"High prevalence of liver fibrosis among european adults with unknown liver disease: a population-based study","volume":"16","author":"Caballer\u00eda","year":"2018","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268123003836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268123003836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T04:52:46Z","timestamp":1713588766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268123003836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1665268123003836"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2023.101280","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2023.101280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101280"}}